Physician profile
Mohammed Ibrahim
NPI 1891701082
$7,365.99
in general payments reported to CMS, 2019-2025
50 companies · $1,989 in 2025
The $1,989 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,330 · 2020: $168 · 2021: $84.17 · 2022: $792 · 2023: $915 · 2024: $2,087 · 2025: $1,989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,877 · Long Term Medical Supply Or Device Loan: $2,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,877.05 |
| Long Term Medical Supply Or Device Loan | $2,114.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,639.20 | 2019-2025 | |
| Genentech USA, INC. | $687.53 | 2019-2025 | Tecentriq, Alecensa, Venclexta |
| Pfizer INC. | $420.83 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $334.99 | 2019-2025 | Calquence |
| Eisai INC. | $268.47 | 2019-2024 | |
| Abbvie INC. | $227.70 | 2024-2025 | |
| Genzyme Corporation | $210.38 | 2019-2025 | |
| Glaxosmithkline, LLC. | $168.76 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Astellas Pharma US INC | $165.94 | 2020-2025 | Padcev, Xtandi |
| Amgen INC. | $162.22 | 2019-2023 | Lumakras |
| Janssen Biotech, INC. | $146.29 | 2019-2025 | Rybrevant, Tecvayli, Talvey |
| E.R. Squibb & Sons, L.L.C. | $140.83 | 2019-2023 | Opdivo |
| Merck Sharp & Dohme LLC | $138.86 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Rigel Pharmaceuticals, INC. | $137.63 | 2019-2024 | Rezlidhia, Tavalisse |
| Celgene Corporation | $132.05 | 2019-2024 | Reblozyl, Pomalyst |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.